SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

714

Alexion Pharmaceuticals

ALXN

Looking for leads, investment insights, or competitive intelligence?

CEO

Ludwig N. Hantson

CEO Title

Chief Executive Officer & Director

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

New Haven, CT

Years on Fortune 500 List

-

Employees

3,121

Profile provided by S&P Global.
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$3,08418.4%
Profits ($M)$399.0176.3%
Assets ($M)$13,253
Total Stockholder Equity ($M)$8,694
Market Value — as of March 31, 2017 ($M)$27,297
Profit Ratios
Profit as % of Revenues12.9%
Profits as % of Assets3.0%
Profits as % of Stockholder Equity4.6%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)1.76
EPS % Change (from 2015)162.7%
EPS % Change (5 year annual rate)14.1%
EPS % Change (10 year annual rate)-
Total Return
Total Return to Investors (2016)-35.9%
Total Return to Investors (5 year, annualized)11.3%
Total Return to Investors (10 year, annualized)28.3%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Alexion Pharmaceuticals

These Are the Only 6 Nasdaq Stocks That Didn't Get Crushed Today

Only a few retailers and other stocks made it out alive.

Read More →
Biotech pros' top 8 stock picks

Breakthroughs in the lab are driving big returns -- but beware the meltdowns.

Read More →
8 pricey stocks haunting the Nasdaq

Problem underscores a glaring weakness in cap-weighted indexes

Read More →
Rare diseases mean big profits for Alexion

The company's strategy: Low volume and high profits centered around just one product - for now.

Read More →